Current Patterns and Best Practices for Prescribing Novel Heart Failure Medications in Children: A Science Advisory From the American Heart Association

Robust evidence from randomized controlled trials of novel heart failure medications in adults has demonstrated improved quality of life, reduced hospitalizations, and decreased mortality, informing current treatment guidelines. In contrast, data supporting the clinical benefits of newer heart failure therapies in children remain limited. To assess contemporary prescribing practices and clinician perspectives, we surveyed pediatric heart failure physicians across the United States and Canada regarding the use of angiotensin receptor-neprilysin inhibitors, sodium-glucose cotransporter 2 inhibitors, and iron replacement therapy in children. We also reviewed the existing pediatric literature and summarized reported side effects, dosing experience, and practical guidance for the use of these therapies in the absence of rigorous evidence.

Authors

Publication Details

Journal
Circulation Heart Failure
Published
2026-11-19
DOI
https://doi.org/10.1161/hhf.0000000000000092
Primary Topic
Heart Failure Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Current Patterns and Best Practices for Prescribing Novel Heart Failure Medications in Children: A Science Advisory From the American Heart Association

Joseph W. Rossano, Aamir Jeewa, Amanda E. Jacobson‐Kelly, David E. Procaccini et al.
Circulation Heart Failure
Heart Failure Treatment and Management
article

Current Patterns and Best Practices for Prescribing Novel Heart Failure Medications in Children: A Science Advisory From the American Heart Association

Joseph W. Rossano, Aamir Jeewa, Amanda E. Jacobson‐Kelly, David E. Procaccini, Borah J. Hong, Jack F. Price, Vernat Exil, Jonathan Menachem, Hugo Martinez, Kimberly Lin
article en

Abstract

Robust evidence from randomized controlled trials of novel heart failure medications in adults has demonstrated improved quality of life, reduced hospitalizations, and decreased mortality, informing current treatment guidelines. In contrast, data supporting the clinical benefits of newer heart failure therapies in children remain limited. To assess contemporary prescribing practices and clinician perspectives, we surveyed pediatric heart failure physicians across the United States and Canada regarding the use of angiotensin receptor-neprilysin inhibitors, sodium-glucose cotransporter 2 inhibitors, and iron replacement therapy in children. We also reviewed the existing pediatric literature and summarized reported side effects, dosing experience, and practical guidance for the use of these therapies in the absence of rigorous evidence.

Circulation Heart Failure
Heart Failure Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon